Abvc biopharma provides vitargus® update

Fremont, ca, aug. 26, 2021 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today provided an update regarding recent developments in connection with vitargus®, the world's first bio-degradable vitreous substitute intended to facilitate retina re-attachment surgery. early clinical studies indicate that vitargus® has unique properties that result in eliminating the need for post-surgery patient face-down positioning, as well as significantly greater recovery period patient comfort and visual acuity than currently available products.
ABVC Ratings Summary
ABVC Quant Ranking